| Health / Medical Topics |
ALVAC-MART-1 Vaccine
A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential immunostimulatory and antineoplastic activities. Upon administration, the MART-1 epitope is expressed by the ALVAC vector in ALVAC-MART-1 vaccine; a host cytotoxic T lymphocyte (CTL) response against MART-1-expressing tumor cells may follow, resulting in tumor cell lysis and decreased tumor cell proliferation. (NCI Thesaurus)
YOU MAY ALSO LIKE
A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an…
A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic…
A cancer vaccine made with a form of the canarypox virus that does not cause disease in people. It is being studied…
A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It…
A replication-defective recombinant canarypox virus (ALVAC) that contains the entire human carcinoembryonic antigen (CEA) gene. Vaccination with ALVAC-CEA (VCP248) may stimulate…
A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-CEA (6D)-B7.1 vaccine expresses both…
